Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer

Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Demel, Uta M., Böger, Marlitt, Yousefian, Schayan, Grunert, Corinna, Zhang, Le, Hotz, Paul W., Gottschlich, Adrian, Köse, Hazal, Isaakidis, Konstandina, Vonficht, Dominik, Grünschläger, Florian, Rohleder, Elena, Wagner, Kristina, Dönig, Judith, Igl, Veronika, Brzezicha, Bernadette, Baumgartner, Francis, Habringer, Stefan, Löber, Jens, Chapuy, Björn, Weidinger, Carl, Kobold, Sebastian, Haas, Simon, Busse, Antonia B., Müller, Stefan, Wirth, Matthias, Schick, Markus, Keller, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057585/
https://www.ncbi.nlm.nih.gov/pubmed/35499080
http://dx.doi.org/10.1172/JCI152383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057585/
https://www.ncbi.nlm.nih.gov/pubmed/35499080
http://dx.doi.org/10.1172/JCI152383

Ejemplares similares